Bile Biochemistry as a Therapeutic Target in Biliary Surgery: Disease-Specific Evidence and Clinical Limits
Authors:
- Zelimkhan BerikkhanovZBZelimkhan Berikkhanov
- Zakhar AkulovZAZakhar Akulov
- Mihail EmcevMEMihail Emcev
- Evgeniy TarabrinETEvgeniy Tarabrin
- Alexey ShestakovASAlexey Shestakov
- Aleksey KotelnikovAKAleksey Kotelnikov
- Andrey NikolaevANAndrey Nikolaev
- Vadim RazumovskyVRVadim Razumovsky
- Milena IvanovaMIMilena Ivanova
- Mehrshad EbrahimnezhadMEMehrshad Ebrahimnezhad
- Sara NourmahalSNSara Nourmahal
- Sergey MuravievSMSergey Muraviev
Open Access
- 28 September 2026
- journal article
- review article
- Published by MDPI AG in Metabolites
- Vol. 16 (10) , 721
Abstract
Background/Objectives: Bile acid therapies have expanded treatment options for cholestatic disease, but their relevance to biliary surgery depends on the diagnosis and endpoint. This critical narrative review examines where molecular evidence changes care and where surgical applications remain untested. Methods: The existing synthesis was supplemented by targeted literature searches and regulatory checks completed on 20 September 2026. Studies were assessed by design, population, outcome, and applicability to surgical decisions. Results: Genetic assessment can identify inherited cholestasis or selected recurrent lithogenic disorders that persist after anatomical treatment. Evidence for ileal bile acid transporter inhibitors supports indication-specific relief of cholestatic pruritus. Recent trials of receptor agonists show that biochemical, symptomatic, and disease-progression outcomes can diverge. Observational studies support biliary diversion in selected patients with inherited cholestasis, although comparisons among procedures and with drug treatment remain uncertain. The expanding genetic spectrum of progressive familial intrahepatic cholestasis and real-world treatment reports refine patient selection but provide limited evidence for long-term surgical outcomes. Bile metabolomics and synthesis markers remain unvalidated for timing cholecystectomy. Conclusions: Molecular findings are useful when they answer a defined diagnostic or therapeutic question. They can guide specialist treatment and surveillance alongside anatomical assessment. Prospective studies must establish whether molecular stratification improves outcomes in biliary surgical populations.Keywords
This publication has 100 references indexed in Scilit:
- Treatment of intractable pruritus with maralixibat in patients with Alagille syndrome before and after reversal of biliary diversionJPGN Reports, 2025
- Real‐world experience of maralixibat in Alagille syndrome: Novel findings outside of clinical trialsJournal of Pediatric Gastroenterology and Nutrition, 2024
- Organic Solute Transporter Alpha Deficiency: A Disorder With Cholestasis, Liver Fibrosis, and Congenital DiarrheaHepatology, 2020
- A Randomized, Controlled, Phase 2 Study of Maralixibat in the Treatment of Itching Associated With Primary Biliary CholangitisHepatology Communications, 2019
- Organic solute transporter‐β (SLC51B) deficiency in two brothers with congenital diarrhea and features of cholestasisHepatology, 2018
- Targeted pharmacotherapy in progressive familial intrahepatic cholestasis type 2: Evidence for improvement of cholestasis with 4‐phenylbutyrateHepatology, 2015
- Sodium taurocholate cotransporting polypeptide (SLC10A1) deficiency: Conjugated hypercholanemia without a clear clinical phenotypeHepatology, 2014
- 4-phenylbutyrate enhances the cell surface expression and the transport capacity of wild-type and mutated bile salt export pumpsHepatology, 2007
- Cellular regulation of hepatic bile acid transport in health and cholestasisHepatology, 2004
- A mutation in the human canalicular multispecific organic anion transporter gene causes the Dubin-Johnson syndromeHepatology, 1997